Theriva Biologics (NYSEAMERICAN:TOVX), traded on the NYSE American under the ticker TOVX, is a clinical-stage biotechnology company dedicated to the development and manufacturing of plasmid DNA-based therapeutics. Leveraging a proprietary high-yield plasmid production platform, the company focuses on creating both prophylactic vaccines and novel gene therapies aimed at addressing infectious diseases and immunological disorders. Headquartered in Cambridge, Massachusetts, Theriva Biologics maintains research and development facilities in the greater Boston area, supporting discovery, process development, and early-stage clinical activities.
The company’s lead product candidates include a multivalent prophylactic vaccine targeting human papillomavirus (HPV) strains not covered by current market offerings and an investigational gene therapy designed to treat chronic Lyme disease through sustained antigen expression. Theriva’s plasmid manufacturing process is designed to deliver high purity and scalability, enabling both internal pipeline programs and potential contract development and manufacturing organization (CDMO) partnerships with larger pharmaceutical firms. This platform-driven approach helps streamline development timelines and reduce production costs.
Since its founding in 2018, Theriva Biologics has pursued strategic collaborations across North America, Europe and the Asia-Pacific region. The company has entered into research agreements with leading academic institutions and emerging biotech companies, underscoring its commitment to fostering innovation through shared expertise. Operational hubs in the United States and a regulatory affairs office in Europe support global clinical trial initiatives and regulatory submissions.
Under the leadership of Chief Executive Officer Dr. Michelle Lee, a veteran biopharmaceutical executive with more than 20 years of industry experience, Theriva Biologics has grown its leadership team to include professionals in manufacturing, clinical development and corporate strategy. The company’s board of directors comprises experts in molecular biology, vaccine formulation and commercial strategy, positioning Theriva to advance its clinical-stage portfolio toward potential regulatory approvals and commercial manufacturing partnerships.
